IS6687A - Pýrasólafleiður - Google Patents

Pýrasólafleiður

Info

Publication number
IS6687A
IS6687A IS6687A IS6687A IS6687A IS 6687 A IS6687 A IS 6687A IS 6687 A IS6687 A IS 6687A IS 6687 A IS6687 A IS 6687A IS 6687 A IS6687 A IS 6687A
Authority
IS
Iceland
Prior art keywords
pýrasólafleiður
Prior art date
Application number
IS6687A
Other languages
English (en)
Inventor
Blair Cooper Christopher
John Helal Christopher
Allen Sanner Mark
T. Wager Travis
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS6687A publication Critical patent/IS6687A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/40Acylated on said nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6687A 2000-08-31 2003-01-16 Pýrasólafleiður IS6687A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22941500P 2000-08-31 2000-08-31
PCT/IB2001/001540 WO2002018346A1 (en) 2000-08-31 2001-08-24 Pyrazole derivatives and their use as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
IS6687A true IS6687A (is) 2003-01-16

Family

ID=22861151

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6687A IS6687A (is) 2000-08-31 2003-01-16 Pýrasólafleiður

Country Status (38)

Country Link
EP (1) EP1313710A1 (is)
JP (1) JP2004507526A (is)
KR (1) KR20030027093A (is)
CN (1) CN1518543A (is)
AP (1) AP2001002266A0 (is)
AR (1) AR035345A1 (is)
AU (1) AU2001280009A1 (is)
BG (1) BG107455A (is)
BR (1) BR0113574A (is)
CA (1) CA2420363A1 (is)
CR (1) CR6881A (is)
CZ (1) CZ2003468A3 (is)
DO (1) DOP2001000243A (is)
DZ (1) DZ3398A1 (is)
EA (1) EA200300205A1 (is)
EC (1) ECSP034480A (is)
EE (1) EE200300085A (is)
GT (1) GT200100179A (is)
HN (1) HN2001000192A (is)
HR (1) HRP20030140A2 (is)
HU (1) HUP0302669A3 (is)
IL (1) IL154016A0 (is)
IS (1) IS6687A (is)
MA (1) MA26946A1 (is)
MX (1) MXPA03001785A (is)
NO (1) NO20030958D0 (is)
NZ (1) NZ523656A (is)
OA (1) OA12368A (is)
PA (1) PA8528101A1 (is)
PE (1) PE20020470A1 (is)
PL (1) PL360742A1 (is)
SK (1) SK2002003A3 (is)
SV (1) SV2002000618A (is)
TN (1) TNSN01132A1 (is)
UY (1) UY26909A1 (is)
WO (1) WO2002018346A1 (is)
YU (1) YU14703A (is)
ZA (1) ZA200301064B (is)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2005504093A (ja) * 2001-09-27 2005-02-10 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 内因性テストステロンレベルの増加方法
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
ATE393159T1 (de) * 2002-07-17 2008-05-15 Pfizer Italia Srl Heterobicyclische pyrazolderivate als kinaseinhibitoren
AU2003263518A1 (en) 2002-10-09 2004-05-04 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
JP2006504755A (ja) * 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Gsk−3阻害薬としてのピリダジン化合物
JP2006519234A (ja) * 2003-02-27 2006-08-24 スミスクライン ビーチャム コーポレーション 新規化合物
ATE384264T1 (de) 2003-05-20 2008-02-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe mit kinasehemmender wirkung
WO2005009344A2 (en) * 2003-06-05 2005-02-03 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
AU2004261459B2 (en) 2003-07-22 2008-06-26 Astex Therapeutics Limited 3, 4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
CA2532231A1 (en) * 2003-07-25 2005-02-03 Pfizer Inc. Aminopyrazole compounds and use as chk1 inhibitors
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
US7244757B2 (en) 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
US20090227648A1 (en) * 2004-04-21 2009-09-10 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2006004865A1 (en) * 2004-06-29 2006-01-12 Rigel Pharmaceuticals, Inc. 2-substituted quinoline compounds and their uses as inhibitors of the ige receptor signaling cascade
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
WO2006055831A2 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
CN101155800B (zh) 2005-02-04 2012-05-23 阿斯利康(瑞典)有限公司 可用作激酶抑制剂的吡唑基氨基吡啶衍生物
WO2006085685A1 (ja) * 2005-02-09 2006-08-17 Takeda Pharmaceutical Company Limited ピラゾール化合物
PL1853588T3 (pl) 2005-02-16 2008-11-28 Astrazeneca Ab Związki chemiczne
MX2007014328A (es) 2005-05-16 2008-02-12 Astrazeneca Ab Compuestos quimicos.
EP1741708A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7563787B2 (en) 2005-09-30 2009-07-21 Miikana Therapeutics, Inc. Substituted pyrazole compounds
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Pde阻害による神経新生の調節
AU2006307657B2 (en) 2005-10-28 2010-10-28 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
NZ594383A (en) 2005-11-03 2013-05-31 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2416155A1 (en) 2006-10-18 2012-02-08 Periness Ltd. Selecting sperm cells in a sperm cell population for use in an assited reproduction technique
JP5406030B2 (ja) * 2006-10-21 2014-02-05 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ3阻害薬としての使用
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン,インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
EA019104B1 (ru) 2007-09-21 2014-01-30 Эррей Биофарма Инк. Активаторы глюкокиназы
JPWO2009130900A1 (ja) * 2008-04-24 2011-08-11 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
HUE027598T2 (en) 2009-04-03 2016-10-28 Hoffmann La Roche Propane-1-sulfonic acid {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-B] pyridine-3-carbonyl] -2,4-difluorophenyl} amide compositions and their uses
US20110081316A1 (en) * 2009-10-02 2011-04-07 Vertex Pharmaceuticals Incorporated Pyrazole inhibitors of phosphatidylinositol 3-kinase
CA2780190C (en) 2009-11-06 2020-05-05 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
CN103119035B (zh) 2010-09-27 2015-09-30 雅培股份有限两合公司 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
ES2671398T3 (es) * 2013-08-16 2018-06-06 Merck Patent Gmbh Derivados de ciclopentilamina 3-sustituida
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
JP2022516057A (ja) 2018-12-31 2022-02-24 バイオメア フュージョン,エルエルシー メニン-mll相互作用の不可逆的阻害剤
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
WO2020157652A2 (en) * 2019-01-31 2020-08-06 Pfizer Inc. Cdk2 inhibitors
WO2022135442A1 (zh) * 2020-12-22 2022-06-30 上海拓界生物医药科技有限公司 Cdk2抑制剂及其制备方法
CN117897384A (zh) 2021-06-28 2024-04-16 缆图药品公司 Cdk2抑制剂
TW202317564A (zh) * 2021-07-01 2023-05-01 大陸商上海拓界生物醫藥科技有限公司 Cdk2抑制劑及其製備方法和用途
WO2023083201A1 (zh) * 2021-11-09 2023-05-19 上海拓界生物医药科技有限公司 一种氨基吡唑衍生物及其制备方法和用途
WO2023092088A1 (en) * 2021-11-19 2023-05-25 Blueprint Medicines Corporation Cdk2 inhibitors and methods of making and using same
WO2023239629A1 (en) * 2022-06-06 2023-12-14 Plexium, Inc. Compounds and pharmaceutical compositions that degrade cdk2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0101704A3 (en) * 1997-12-22 2002-12-28 Bayer Corp Pittsburgh Kinease substituted heterocyclic ureas with raf inhibition activity and pharmaceutical compositions containing them
KR100579792B1 (ko) * 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
AU6314900A (en) * 1999-07-26 2001-02-13 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
GEP20053476B (en) * 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
EE200200275A (et) * 1999-11-30 2003-10-15 Pfizer Products Inc. Immunosupressantidena kasutatavad 2,4-diaminopürimidiiniühendid
WO2001079198A1 (en) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase

Also Published As

Publication number Publication date
YU14703A (sh) 2006-05-25
HRP20030140A2 (en) 2003-04-30
AP2001002266A0 (en) 2001-09-30
ECSP034480A (es) 2003-03-31
CN1518543A (zh) 2004-08-04
EE200300085A (et) 2004-12-15
ZA200301064B (en) 2004-04-19
WO2002018346A1 (en) 2002-03-07
DZ3398A1 (fr) 2002-03-07
AU2001280009A1 (en) 2002-03-13
MXPA03001785A (es) 2003-06-04
CZ2003468A3 (cs) 2004-05-12
PE20020470A1 (es) 2002-06-18
OA12368A (en) 2004-04-13
HUP0302669A2 (hu) 2003-12-29
IL154016A0 (en) 2003-07-31
HUP0302669A3 (en) 2004-03-29
HN2001000192A (es) 2001-08-28
CA2420363A1 (en) 2002-03-07
KR20030027093A (ko) 2003-04-03
BR0113574A (pt) 2003-07-22
AR035345A1 (es) 2004-05-12
TNSN01132A1 (fr) 2005-11-10
MA26946A1 (fr) 2004-12-20
NZ523656A (en) 2004-11-26
SK2002003A3 (en) 2004-04-06
NO20030958L (no) 2003-02-28
DOP2001000243A (es) 2002-10-15
PA8528101A1 (es) 2002-07-30
EP1313710A1 (en) 2003-05-28
UY26909A1 (es) 2002-03-22
PL360742A1 (en) 2004-09-20
BG107455A (en) 2003-09-30
JP2004507526A (ja) 2004-03-11
EA200300205A1 (ru) 2003-06-26
CR6881A (es) 2004-03-11
SV2002000618A (es) 2002-10-24
GT200100179A (es) 2002-04-22
NO20030958D0 (no) 2003-02-28

Similar Documents

Publication Publication Date Title
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
IS6687A (is) Pýrasólafleiður
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
ATE312098T1 (de) Thiazinoxazolidinon
ATA2932001A (de) Schneefräse
DE50102988D1 (de) Bodenwischer
DE50104056D1 (de) Gewichtsmanschette
DE50100710D1 (de) Wischblatt
ATE262530T1 (de) Indolochinazolinone
ATE298751T1 (de) 7-oxopyridoryrimidine
DE1274523T1 (de) Hochdruckumformspülanlage
DE50104651D1 (de) Fahrzeugfaltverdeck
DE10192638T1 (de) Bohrstangenladevorrichtung
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
DE10196064T1 (de) Halbleiterfotodektionsgerät
DE50100817D1 (de) Kugelgelenk
DE50011511D1 (de) Blowby-Heizung
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
AR027931A1 (es) Antitranspirantes
ATE476423T1 (de) Benzoylpyridazine
DE10052925B4 (de) Schaukelbett
DE10195909T1 (de) Viehfüttervorrichtung
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung
AR027982A1 (es) Aril- y heteroarilsulfonatos